Fontan结局网络:2年1121名参与者的研究发现
Fontan结局网络是一项覆盖美国和加拿大38个先天性心脏病中心的学习型健康网络,报告前1121名前瞻性注册参与者的基线特征与早期横断面分析结果。参与者平均年龄16.3±10.2岁,42%为女性,59%存在典型Fontan相关不良事件,41.3%有心律失常病史,34.1%临床诊断焦虑障碍。
要点
- Fontan相关不良事件报告率为59%,包括乳糜胸、Fontan血栓和非围手术期卒中
- 心律失常病史随年龄增长而增加,总体达41.3%
- 焦虑障碍在成人中达48.1%,提示需关注心理健康需求
核心结论
- Fontan结局网络纳入目前最大的Fontan循环患者前瞻性多机构数据集之一,初步结果显示协作学习健康网络有望推动该罕见病人群的研究与质量改进。
研究设计与样本
- 对2022年8月至2024年8月纳入Fontan结局网络、接受过Fontan姑息手术的个体进行横断面分析,按年龄组(<12岁、12至<18岁、≥18岁)描述人口学、临床、影像、操作及用药数据。
- Fontan结局网络为美国与加拿大38个先天性心脏病中心组成的学习型健康网络。
主要发现
- 共纳入1121名参与者,平均年龄16.3±10.2岁,471名(42%)为女性。
- 最常见原发心脏诊断为左心发育不良综合征(431例,38.5%)和右心室优势解剖(615例,54.9%),在低年龄组尤为常见。
- 心外管道为最常见Fontan类型(749例,66.8%)。
- 59%病例(662例)存在典型Fontan相关不良事件,包括乳糜性胸腔积液(108例,9.6%)、Fontan血栓(79例,7.1%)和非围手术期卒中(73例,6.5%)。
- 心律失常病史总体为41.3%(463例),随年龄增长而增加;获得性合并症为57.5%(645例),包括哮喘(132例,12%)和睡眠呼吸暂停(103例,9%),负担随年龄增加。
关键数值与推荐
- 抗血栓药物使用几乎普遍;其他药物使用随年龄差异较大,包括β受体阻滞剂、血管紧张素转换酶抑制剂和肺血管扩张剂。
- 心律失常病史总体41.3%,焦虑障碍总体34.1%、成人48.1%,抗抑郁药总体11.8%、成人23.6%。
临床怎么用
- 对Fontan循环患者应关注心律失常、血栓、卒中及乳糜胸等Fontan相关不良事件,并随年龄增长加强合并症筛查。
- 成人Fontan患者中焦虑障碍和抗抑郁药使用比例较高,提示应将心理健康评估与干预纳入常规随访。
局限性
- 本文为横断面描述性分析,未报告随访结局或因果推断。
- 原文未报告样本代表性、失访及数据完整性等局限性的具体说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular-dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.
引用
- Glenn TM, Kasparian NA, Amdani S, et al. The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. Circulation. 2026. PMID: 41878814. doi:10.1161/CIRCULATIONAHA.125.078152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。